PMID- 36684415
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230201
IS  - 1176-9351 (Print)
IS  - 1176-9351 (Electronic)
IS  - 1176-9351 (Linking)
VI  - 22
DP  - 2023
TI  - Immunogenetic Profiles and Associations of Breast, Cervical, Ovarian, and Uterine 
      Cancers.
PG  - 11769351221148588
LID - 10.1177/11769351221148588 [doi]
LID - 11769351221148588
AB  - It is increasingly recognized that the human immune response influences cancer 
      risk, progression, and survival; consequently, there is growing interest in the 
      role of human leukocyte antigen (HLA), genes that play a critical role in 
      initiating the immune response, on cancer. Recent evidence documented clustering 
      of cancers based on immunogenetic profiles such that breast and ovarian cancers 
      clustered together as did uterine and cervical cancers. Here we extend that line 
      of research to evaluate the HLA profile of those 4 cancers and their 
      associations. Specifically, we evaluated the associations between the frequencies 
      of 127 HLA alleles and the population prevalences of breast, ovarian, cervical, 
      and uterine cancer in 14 countries in Continental Western Europe. Factor analysis 
      and hierarchical clustering were used to evaluate groupings of cancers based on 
      their immunogenetic profiles. The results documented highly similar immunogenetic 
      profiles for breast and ovarian cancers that were characterized predominantly by 
      protective HLA effects. In addition, highly similar immunogenetic profiles for 
      cervical and uterine cancers were observed that were, conversely, characterized 
      by susceptibility effects. In light of the role of HLA in host immune system 
      protection against non-self antigens, these findings suggest that certain cancers 
      may be associated with similar contributory factors such as viral oncoproteins or 
      neoantigens.
CI  - (c) The Author(s) 2023.
FAU - James, Lisa M
AU  - James LM
AD  - Department of Veterans Affairs Health Care System, The HLA Research Group, Brain 
      Sciences Center, Minneapolis, MN, USA.
AD  - Department of Neuroscience, University of Minnesota Medical School, Minneapolis, 
      MN, USA.
AD  - Department of Psychiatry, University of Minnesota Medical School, Minneapolis, 
      MN, USA.
FAU - Georgopoulos, Apostolos P
AU  - Georgopoulos AP
AD  - Department of Veterans Affairs Health Care System, The HLA Research Group, Brain 
      Sciences Center, Minneapolis, MN, USA.
AD  - Department of Neuroscience, University of Minnesota Medical School, Minneapolis, 
      MN, USA.
AD  - Department of Psychiatry, University of Minnesota Medical School, Minneapolis, 
      MN, USA.
AD  - Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20230116
PL  - United States
TA  - Cancer Inform
JT  - Cancer informatics
JID - 101258149
PMC - PMC9846304
OTO - NOTNLM
OT  - Breast cancer
OT  - cervical cancer
OT  - genetics
OT  - human leukocyte antigen
OT  - immunity
OT  - ovarian cancer
OT  - uterine cancer
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2023/01/24 06:00
MHDA- 2023/01/24 06:01
PMCR- 2023/01/16
CRDT- 2023/01/23 04:23
PHST- 2022/10/31 00:00 [received]
PHST- 2022/12/13 00:00 [accepted]
PHST- 2023/01/23 04:23 [entrez]
PHST- 2023/01/24 06:00 [pubmed]
PHST- 2023/01/24 06:01 [medline]
PHST- 2023/01/16 00:00 [pmc-release]
AID - 10.1177_11769351221148588 [pii]
AID - 10.1177/11769351221148588 [doi]
PST - epublish
SO  - Cancer Inform. 2023 Jan 16;22:11769351221148588. doi: 10.1177/11769351221148588. 
      eCollection 2023.